Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
Claudia O. Gambrah-Sampaney, MD, Jesse E. Passman, MD, MPH, Andrielle Yost, MPA, and Glen N. Gaulton, PhD
In the past decade, more students than ever entered medical school with the desire, if not the expectation, of participating in meaningful global health experiences.
AMA J Ethics. 2019;21(9):E772-777. doi:
10.1001/amajethics.2019.772.
How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Kelly Leonard, executive director of insights and applied improvisation at Second City Works, relates how improvisation can help clinicians build relationships with patients and improve their outcomes.